Latest Breaking News On - Stephen machatha - Page 1 : comparemela.com

At the current valuation, the market is more optimistic about Aldeyra's approach to RASP and prospects for lead program reproxalap. Click here to see why ALDX is a Buy.

United statesBruce greenbergTodd bradyStephen machathaJoshua reedAllergan abbvieCubist pharmaceuticalsLigand pharmaceuticalsCydex pharmaceuticalsKala pharmaceuticalsAldeyra therapeuticsEye summaryController bruce greenbergPerceptive advisorsChief development officer stephen machathaSynageva biopharmaceuticals